A Thorough Look at the Different Surgical Choices for Ulcerative Colitis: How Various Medical Experts Work Together to Understand the Latest Treatments, New Possibilities, and What Might Come Next in the Field

[1]Akash Sarkar, [2]Hrittesh Ghosh, [3]Musharapov Denis Razikovich

[1]MD Candidate, Certificate in Clinical Neurology (C. Neuro), London, UK, Fellowship researcher (AIPU), Department of General Medicine, Bashkir State Medical University, Ufa, Russia

[2]MD Candidate, Fellowship researcher (AIPU), Department of General Medicine, Bashkir State Medical University, Ufa, Russia

[3]Professor, MD, PhD, Department of Surgery, Bashkir State Medical University, Ufa, Russia

DOI: https://dx.doi.org/10.51244/IJRSI.2026.1305000106

Received: 24 April 2026; Accepted: 30 April 2026; Published: 02 June 2026

ABSTRACT

Acute severe ulcerative colitis is a very serious ailment that involves hospital treatment and inhalation of powerful drugs such as intravenous steroids. About one-third of the individuals affected by this situation fail to show improvement with steroids alone, thus requiring other special medications. Infliximab or cyclosporine can be given to these patients as the means of treatment. The two drugs turn out to be equally effective, but doctors commonly choose infliximab because they find it more convenient and they have adequate experience of working with it. Nevertheless, should a patient have already been exposed to infliximab previously, then doctors are allowed to prescribe cyclosporine more frequently. When folks with severe ulcerative colitis do not respond positively to such therapies, the next step could be the surgical intervention, i.e., excision of the colon. The medical community is very active in looking for more ways of treating the condition that do not involve surgery. Previous studies have shown that medicines like Janus kinase inhibitors are of great help when applied together with steroids at the beginning or used as a single treatment, respectively, though their effectiveness still needs to be established through further research.

Keywords: Ulcerative operation, bowel movement, Corticosteroid, immunomodulatory, Crohn’s disease, ulcer

INTRODUCTION

Some data are known about ulcerative colitis. This is also known as a habitual complaint. Ulcerative colitis is a complex complaint that results in inflammation and the conformation of ulcers in the inner stuffing of the large intestine, including the colon and the rectum, which is the last part of the colon. UC is one of the two main types of habitual inflammatory conditions of the gastrointestinal tract, known as inflammatory bowel complaint (IBD). The other form is called Crohn's complaint. generally, the large intestine is responsible for absorbing water from excreta, which changes it from liquid to solid. still, in UC, the inflammation causes the loss of the colon’s stuffing, which leads to bleeding, pus, diarrhoea, and abdominal discomfort.

ULCERATIVE COLITIS CAUSES

The exact cause of UC is not known, though there are some theories. People with UC have issues with their immune system, but it's still unclear whether these problems are the cause of the disease or a result of it. The

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue V May 2026

immune system helps protect the body from infection by recognizing and destroying harmful substances like bacteria and viruses. In UC, it's thought that the body's immune system reacts in an unusual way to bacteria in the digestive tract. UC can sometimes run in families, and research has shown that certain genetic problems are more common in people with UC. Sensitivity to certain foods or food products doesn't cause UC, but it may trigger symptoms in some individuals. UC is not caused by emotional distress, but the stress of living with the condition can make symptoms worse. In addition, while sensitivity to certain foods or food products doesn't cause UC, it may trigger symptoms in some people. Ulcerative colitis causes

HIGH RISK WHO ARE GETTING UC

Ulcerative colitis is mainly found in people who have been diagnosed with the condition. The number of people getting ulcerative colitis in the last 50 years has increased, which is especially important. According to the CDC, the occurrence of ulcerative colitis, which means the number of new cases each year, is between 2.2 and 14.3 cases per 100,000 people. The average age when most people are diagnosed with ulcerative colitis is between 35 and 36 years, but the disease can affect people of all ages. Men are more likely to be diagnosed with ulcerative colitis than women, especially in their 50s and 60s. Caucasians are more prone to developing ulcerative colitis compared to people from other racial or ethnic backgrounds. This is why both ulcerative colitis and Crohn's disease are more common in northern countries, urban areas, and developed nations. However, most of these patterns are slowly changing. For example, the number of ulcerative colitis patients is increasing in some developing countries like China, India, and South America. In 2021, there were 3.8 million people with IBD, with an incidence rate of 4.4 and a death rate of 0.5 per 100,000 people. The overall incidence rate increased between 1990 and 2021, but during the same time, the death rate, prevalence, and disability-adjusted life year rates decreased. The age-standardized death rate (ASDR) hardly increased in most regions and countries from 2019 to 2021. Western Europe still had a high burden, while East Asian countries, especially China, experienced a sharp rise in new cases. The age-standardized rates are related to the incidence and death rates, and they increase with higher socio-demographic indexes.

GENETIC FACTOR OF UC

A group of scientists has made a finding that ulcerative colitis is likely to be inherited. Namely, during the family risk for getting IBD, it is estimated to be between 1.5 percent and 28 percent for an affected person's first-degree relatives. On the one hand, genetics is surely a key factor, on the other hand, dietary habits, lack of exercise, or exposure to some pollutants could be environmental factors that trigger the onset, progression, and relapse of the disease. In this light, even though the family history has a credible influence on the increased risk of IBD, it actually remains impossible to accurately determine who, if any, the family members are that would develop ulcerative colitis. People who have relatives diagnosed with ulcerative colitis do not have to take the test right away as a routine measure. If the family members on that side of the family get symptoms, they also need a check-up by a gastroenterologist. Some conditions come with symptoms that are almost indistinguishable from IBD, and as such getting a clear diagnosis is vital.

SIGN & SYMPTOMS OF UC

The most common symptoms of UC are breadbasket pain and blood or mucus in the coprolite. Other symptoms include anaemia, fatigue, fever, nausea, weight loss, loss of appetite, rectal bleeding, loss of body fluids and nutrients, skin problems, and slow growth in children. utmost people with UC have mild to moderate symptoms. About 10 percent have severe symptoms like frequent complications, bloody diarrhoea, nausea, and strong breadbasket cramps. UC can also lead to other issues similar as common pain, eye problems, order monuments, liver complaint, and weak bones. Croakers do not know why these problems be, but they suppose they may be caused by the body's vulnerable system replying too much. Some of these problems go down when UC is treated.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue V May 2026



Figure- ulcerative colitis

PATHOPHYSIOLOGY

UC, as a recurrent and refractory digestive disease, is closely associated with colorectal cancer, but the exact aetiology has not yet been determined (13). UC is greater customary in developed international locations than in growing countries, however the incidence in creating nations is getting greater and higher. The gut microbiota, mucosal barrier damage, and immune response regulation are affected by nutritional imbalance and dietary factors. While UC can occur in people of any age, it usually develops between the ages of 15 and 30and less frequently between the ages of 60 and 80. The disease affects men and women equally. People with a family member or first-degree relative with an IBD are at higher risk for developing UC, as are Caucasians and people of Jewish descent. The pathogenesis of UC is driven by gene-environment interactions leading to an abnormal immune system response to the intestinal microbiome. More than 200 genetic loci have been associated with UC. Environmental exposures may predispose an individual to UC by influencing the diversity and composition of the 1 trillion bacteria, viruses, and fungi that form the intestinal microbiome.

LABORATORY TEST OF UC

Diagnosis and Testing of Ulcerative Colitis Healthcare workers perform a colonoscopy and take tissue samples, known as biopsies, from inside the colon to diagnose ulcerative colitis. Other types of inflammatory bowel disease, such as Crohn's disease, can also be checked with additional tests like stool tests, MRI, and CT scans. Including one or more of the following tests and procedures may be part of the treatment plan for someone with ulcerative colitis.

BLOOD TESTS.

The doctor might suggest blood tests to check for anemia or signs of infection. Anemia is a condition where the body doesn't have enough red blood cells to carry oxygen to the organs. In some cases, they also look for signs of inflammation.

STOOL STUDIES.

The presence of white blood cells or certain proteins in the stool can help diagnose ulcerative colitis. A stool sample can also help rule out other issues like bacterial, viral, or parasitic infections.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue V May 2026

ENDOSCOPIC PROCEDURES:

COLONOSCOPY.

Using a thin, flexible tube with a camera at the end, the healthcare professional checks the entire large intestine. They take tissue samples during the procedure for testing in the lab. This process is called a biopsy, and one of these samples is needed for identification.

FLEXIBLE SIGMOIDOSCOPY.

Similar to a colonoscopy, this procedure uses a thin, flexible, lighted tube with a camera. However, the tube is shorter and is used to examine the rectum and sigmoid colon, which are the last parts of the colon. When the colon is very inflamed, this test might be used instead of a full colonoscopy.

IMAGING PROCEDURES:

X-RAY.

If symptoms like stomach discomfort are very severe, a standard abdominal X-ray is done first to check for a swollen colon. A swollen colon can cause serious problems, such as toxic megacolon or a tear in the colon wall.

CT SCAN.

A CT scan of the abdomen or pelvis may be performed to check for inflammation. It can also help find an abscess or other causes of pain.

CT ENTEROGRAPHY AND MAGNETIC RESONANCE (MR) ENTEROGRAPHY.

A healthcare professional might recommend one of these non-invasive tests to check for inflammation in the small intestine. These tests are more sensitive in detecting inflammation than traditional imaging tests. MR enterography is a radiation free alternative to other diagnostic imaging methods.

HISTOPATHOLOGY

The biopsy method and the histopathological analysis are both important for accurately classifying and separating ulcerative colitis (UC) from other types of colitis. At least two biopsy samples must be taken from each of the six areas examined, which include the terminal ileum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum. The chosen samples should be from normal-looking mucosa and should be fixed immediately after collection in buffered formalin. The typical histological changes seen in UC include crypt architectural distortion, mucosal atrophy, and a widespread inflammatory infiltration throughout the mucosa with basal plasmacytosis. Crypts and crypt abscesses are features of active disease. Not all these features are present in stage 1 disease, which shows that basal plasmacytosis acts as an early marker that is different from other features [1]. In terms of histology, crypt architectural distortion can be seen even in the early stages of disease and is reported in just 20% of patients who experience symptoms a fortnight before diagnosis. By contrast, basal plasmacytosis appears earlier and has strong predictive value for UC, helping to distinguish it from infectious colitis, where crypt architecture is usually preserved.

BIOMARKERS

The existing research work being carried out on Ulcerative Colitis (UC) is focusing on biomarkers that are currently dealing mainly with the replacement of invasive procedures like colonoscopies with modern, non-invasive, molecular-based devices for monitoring disease activity and response to treatment predictions. These developments are making a significant impact on the field.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue V May 2026

CONFIRMED CLINICAL BIOMARKERS

Even though many new markers are continually emerging, the ones listed in the most recent clinical guidelines, such as those from the American Gastroenterological Association (AGA), emphasize the following three primarily non-invasive methods of monitoring:

1. Fecal Calprotectin (FCP): The most common marker of mucosal inflammation, a neutrophil-derived protein. Typically, active inflammation in patients in symptomatic remission is ruled out when FCP levels are <150 µg/g.
2. Fecal Lactoferrin: An iron-binding glycoprotein found in neutrophils, used similarly to calprotectin to identify active Inflammatory Bowel Disease (IBD).
3. C-Reactive Protein (CRP): A serum substance synthesized by the liver during the acute-phase response. Although it is a nonspecific indicator, its use in monitoring control of flare and effect of treatment is very efficient, particularly in severe cases.

THE NEWEST MOLECULAR AND GENETIC BIOMARKERS

Recent research articles highlight groundbreaking candidates for specific UC activity.

1. MicroRNAs (miRNAs): A study published in PMC shows the most significant hallmarks of diagnosis, namely miR-21, miR-126, and miR-146b-5p. For instance, the increase in the level of miR-126 in active UC tissues compared to healthy controls was an 18-fold increase.
2. Gene Signatures: Novel diagnostic markers such as ABCD3 (AUC = 0.9185) and NR3C2 (AUC = 0.9025) are identified using machine learning.
3. Hub Genes: Case studies published in Scientific Reports report that CXCL1, CYP2R1, LPCAT1, and NEU4 are significant activity markers associated with immune cell infiltration.
4. PARP8: Cited as a potential biomarker correlating positively to the presence of neutrophils and M1 macrophages.

PROGNOSTIC AND INVESTIGATIVE MARKERS

1. CAR and NAR Ratios: The C-reactive protein-to-albumin ratio (CAR) and the neutrophil-to-albumin ratio (NAR), although similar, are different and are discovered as the earliest signs of treatment effectiveness, particularly for biologics other than infliximab.
2. Anti-integrin αvβ6 Antibodies: These antibodies are present in 92% of patients with UC (compared to 5.2% of healthy controls), indicating very high specificity for the diagnosis and monitoring of the disease.
3. Fecal Metabolites: Certain compounds such as L-tryptophan and succinic acid are found in much larger amounts during UC exacerbation, however, lithocholic acid is associated with remission.

DIAGNOSIS & TREATMENT

Treatment for ulcerative colitis (UC) depends on the inflexibility of the complaint and its symptoms. drug remedy helps manage symptoms, though it does not cure UC. The pretensions of drug remedy are to induce and maintain absolution ages when symptoms go down for months or indeed times, and to ameliorate the quality of life. numerous people with UC bear drug remedy indefinitely unless they've their colon and rectum surgically removed. The type of drug specified depends on the inflexibility of UC.

AMINOSALICYLATES

These specifics contain 5- aminos alicyclic acid (5- ASA) and help control inflammation.

One similar drug is sulfasalazine (Azulfidine), which is a combination of sulfapyridine and 5- ASA. The sulfapyridine element carries the anti-inflammatory 5- ASA to the bowel. Sulfapyridine may beget side goods similar as nausea, puking, heartburn, diarrhoea, and headache. Other 5- ASA agents, similar as olsalazine (Dipentum), mesalamine (Asacol, Canasa, Lialda, Rowasa), and balsalazide (Colazal), beget smaller side goods

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XIII Issue V May 2026

and can be used by people who cannot take sulfasalazine. Depending on which corridor of the colon and rectum are affected by UC, 5- ASAs can be given orally, through a rectal suppository, or via an enema. Unless UC symptoms are severe, people are generally first treated with aminosalicylates. These specifics are also used when symptoms return after a period of absolution.

INFLIXIMAB (REMICADE)

One of the agents that fall under the order of anti-tumour necrosis factor(anti-TNF) and is recommended for use in cases with UC who fail or cannot use other specifics or 5- ASAs.

Cases on Infliximab must also be given immunomodulators to help antipathetic responses. These immunosuppressive medicines substantially act by inhibiting a protein called TNF from binding with its receptor, which prevents further intestinal inflammation. The medicine is administered intravenously, meaning it's directly invested into the bloodstream through a catheter connected to a tone in the arm and is done every 6 to 8 weeks either at the sanitarium or inpatient settings. Some may witness lateral goods similar as toxin and increased vulnerability to infections, especially tuberculosis. Different drugs can be taken to control the symptoms of anxiety or pain, to manage other problems like diarrhoea, or to get relieve of the infection.

IMMUNOMODULATORY

Agents Azathioprine (Imuran, Azasan), 6- mercaptopurine (6- MP) (Purinethol), and cyclosporine (Neoral, Sandimmun, Sandimmune) are agents that serve on the vulnerable system.

They're used for cases who don't respond to corticosteroids. Immunomodulators are specified orally, but they've a slow onset of action and can take 3- 6 months to come effective. Complications similar as nausea, puking, fatigue, pancreatitis, hepatitis, a dropped white blood cell count, and an increased threat of infection are observed in people taking these medicines and are covered. Cyclosporine is used only for extremely sick UC cases because the frequent side effect is toxin, which can beget long- term goods on the body. In addition, drug has the side effect of periodical toxin, which indicates that it can beget serious consequences in the mortal body over time.

CORTICOSTEROIDS

Corticosteroids, similar as prednisolone, methylprednisolone, and hydrocortisone, are specifics that can also drop inflammation.

They're offered to cases enduring further acute instantiations and those who aren't responsive to 5- ASAs. Also appertained to as steroids, corticosteroids might be used in colourful ways; they can be taken by mouth, invested intravenously, or delivered through an enema, rectal froth, or a suppository depending on what corridor of the colon and rectum are affected by UC. Among the side goods are weight gain, acne, facial hair, hypertension, diabetes, mood swings, bloodied bone mass, and an increased threat of infection. moment people use these medicines only sometimes because side goods are frequently harsh; because of this, steroids aren’t naturally recommended for long- term use. Steroids are generally specified for a specific time frame and also stopped formerly the colon is healed. The remaining specifics used for UC are specified for patient incarnation control.

FUTURE THERAPY

The health-related and social issues of ulcerative colitis stem from its wide range of causes and powerful super viruses as a result. Ulcerative colitis also has a complicated etiology and pathogenesis, which includes genetic disposition, the state of the immune system, environmental factors, the presence of infectious agents, as well as the imbalance between intestinal flora, which among other elements trigger the disease. Notably, ulcerative colitis has a fairly complex pathos that is not comprehended by health experts yet. It entails the involvement of cytokines that are released from macrophages, the main immune system that gets affected, and the possibility that the dysfunction of these cells is one of the core pathogeneses of the disease. Besides, at present, the most

effective instrument in UC diagnosis is the colonoscopy but it is constrained by its being invasive. Medical imaging and other diagnostic tools that will be advanced more include ultrasound, magnetic resonance, calprotectin, and CRP which can actually substitute some tests. As mentioned previously, new targeted therapies that are progressing quickly, such as hormones, cytokines, and immunomodulators, are also coming up with more solutions for UC treatment. Investigating novel bile acid receptor pathways as therapeutic strategies in ulcerative colitis is under progress. Farnesoid X receptor (FXR) is one of the main targets because it is responsible for regulation of mucosal immunity and intestinal barrier function. Agents that activate FXR (farnesoid X receptor) like obetcholic and cilofexor are considered as the techniques to restore epithelial homeostasis through the process of inflammation similar to what drugs, such as multitargets, might do.

CONCLUSION

The end of the article is about the management of ulcerative colitis (UC), which is a particular stage across its remission induction to maintenance and acute treatment. This can be done only through individualized methods related to the severity of the disease and the patient's response to a particular therapy. In the case of mild to moderate UC, oral mesalazine at higher doses and colonic-released budesonide have shown efficacy, and combined therapies are the best option compared to monotherapies. For patients who show inadequate response, the addition of topical steroids and the use of systemic corticosteroids, on the other hand, are the possible alternatives, while the use of thiopurines is not recommended because they have a longer period of onset. In the case of chronic treatments, the use of the same type of mesalazine formulations is crucial in reducing the risk of relapses, while the use of thiopurines is an option only for patients who are intolerant to mesalazine. In moderate to severe UC, the introduction of biologic therapies such as anti-TNF agents, vedolizumab, ustekinumab, and oral small molecules such as Janus kinase inhibitors has resulted in disease control for patients who are steroid refractory or dependent. For acute severe UC, prompt initiation of corticosteroids and multidisciplinary management, particularly in collaboration with IBD surgeons, remains crucial, with salvage options such as infliximab and cyclosporine available for patients who do not respond. Overall, effective treatment requires close monitoring and an individualized approach to achieve optimal clinical and endoscopic responses and improve the quality of life for patients with UC.

REFERENCE

1. Le Berre C, Honap S Peyrin- Biroulet L wrote about Ulcerative Colitis in the Lancet. This was published in 2023. The article is in volume 402 issue 10401 on pages 571 to 584.
2. Ng SC, Shi HY, Hamidi N and others did a study on Ulcerative Colitis. They looked at how common Ulcerative Colitiss around the world. This study was published in the Lancet in 2017. It is in volume 390 issue 10114 on pages 2769 to 2778.
3. Yamazaki M, Chung H, Xu Y and others looked at Ulcerative Colitis trends. They compared Ulcerative Colitis in Japan and the US. This was published in the International Journal of Colorectal Disease in 2023.
4. Voelker R wrote about what Ulcerative Colitiss. This was published in the Journal of the American Medical Association in 2024.
5. Liang Y, Li Y, Lee C and others wrote about Ulcerative Colitis treatment. They talked about using molecules to treat Ulcerative Colitis. This was published in Molecular Biomedicine in 2024.
6. Kaluzna A, Olczyk P, Komosinska- Vassev K, Hebelka H Lagerstrand KM looked at how the immune system affects Ulcerative Colitis. They wanted to know how the immune system helps Ulcerative Colitis start and get worse. This was published in the Journal of Clinical Medicine in 2022.
7. Swirkosz G, Szczygiel A, Logon K and others did a review of the microbiome. They looked at how the microbiome affects Ulcerative Colitis. This was published in Biomedicines in 2023.
8. Ananthakrishnan AN, Murad MH, Scott FI and others compared Ulcerative Colitis treatments. They wanted to know which treatments work best for moderate to Ulcerative Colitis. This was published in Gastroenterology in 2024.
9. Chang S, Murphy M Malter L reviewed the medicines used to treat Ulcerative Colitis. They looked at the medicines that're available to treat moderate to severe Ulcerative Colitis. This was published in the American Journal of Gastroenterology in 2024.

10. Dulai PS, Singh S Jairath V and others talked about using biologics to treat Ulcerative Colitis. They wanted to know how to use these medicines to treat Ulcerative Colitis. This was published in Gastroenterology in 2024.
11. Claytor, Faith JJ Jennifer D and others wrote about Fecal Microbiota Transplantation. They looked at using Fecal Microbiota Transplantation to treat Ulcerative Colitis. This was published in Clinical Gastroenterology and Hepatology in 2024.
12. Bulut Gökten D, Çabuk B, Solakoğlu T and others did a study on arthritis. They looked at how enteropathic arthritis affects people, with Ulcerative Colitis. This was published in the Egyptian Rheumatologist in 2024.
13. Wangchuk P, Yeshi K and Loukas A wrote about Ulcerative Colitis, which includes biomarkers, therapeutic targets and emerging treatments. They published this in Trends Pharmacol Sci in 2024.
14. Thoo L, Noti M and Krebs P talked about the barrier and how it works. They said it is like being at the interface of peace and war. This was published in Cell Death Dis in 2019.
15. Villanacci V, Del Sordo R, Lanzarotto F and others found that Claudin-2 is a marker for evaluating histological mucosal healing in inflammatory bowel diseases. They published this in Dig Liver Dis in 2024.
16. Saez A, Herrero-Fernandez B, Gomez-Bris R and others wrote about the pathophysiology of Inflammatory Bowel Disease and the innate immune system. This was published in Int J Mol Sci in 2023.
17. Wu Y and Shen J talked about extracellular traps in inflammatory bowel disease. They discussed pathways, biomarkers and promising therapies. This was published in Cytokine Growth Factor Rev in 2024.
18. Tyler CJ, Guzman M, Lundborg LR and others found that antibody secreting cells are dependent on integrin alpha4beta7/MAdCAM-1 for recruitment and control of the microbiota during chronic colitis. They published this in Mucosal Immunol in 2022.
19. Grames M, Breviario F Pintucci G and others found that interleukin-1 enhances plasminogen activator inhibitor activity in endothelial cells. This was published in Biochem Biophys Res Commun in 1986.
20. Sanchez-Munoz F, Dominguez-Lopez A and Yamamoto-Furusho JK wrote about the role of cytokines in bowel disease. They published this in World J Gastroenterol in 2008.
21. Nakase H, Sato N Mizuno N and others talked about the influence of cytokines on the pathology of Ulcerative Colitis. This was published in Autoimmun Rev in 2022.
22. Wan X, Zhang C, Lei P and others developed precision therapeutics for bowel disease. They used ROS-nanoparticles for targeted and multifunctional drug delivery. This was published in J Mater Chem B in 2025.
23. Guo J, Li L Cai Y and others developed probiotics and prebiotics therapy for Ulcerative Colitis. This therapy has gained a lot of attention. They published this in Cell Commun Signal in 2024.
24. Do KH, Ko SH, Kim KB and others compared the microbiome in patients with Ulcerative Colitis and healthy controls in Korea. This was published in Microorganisms in 2023.
25. Pandey H, Jain D, Tang DWT and others wrote about the gut microbiota, in the pathophysiology, diagnosis and therapeutics of bowel disease. They published this in Intest Res in 2024.